Investment
Features
FeesSafety
Academy
More
Pluang+

Compare BioNano Genomics Inc (BNGO) vs Byrna Technologies Inc (BYRN) Price & Performance

BioNano Genomics IncTrade
Byrna Technologies IncTrade

Price performance (Past 24H)

Key statistics

BioNano Genomics Inc vs Byrna Technologies Inc — how do they compare? BioNano Genomics Inc trades at $1.19 (market cap $13.66M), while Byrna Technologies Inc trades at $4.34 (market cap $106.74M). The key difference: Byrna Technologies Inc is far larger — about 7.8× BioNano Genomics Inc's market cap. Which is the better fit depends on your goals.

BNGOBYRN
Market Cap
$13.66M$106.74M
Sector
HealthTechnology
52-Week High
$4.92$27.63
52-Week Low
$1.06$3.18
Enterprise Value
$16.26M$98.35M

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

BioNano Genomics Inc

BNGO trades at $1.16 with a bullish technical signal supported by moving averages. The company shows improving financial trends with narrowing losses and consistent earnings beats, though it remains unprofitable with negative margins. Recent news highlights operational progress including debt retirement and scientific publications. Valuation ratios appear attractive with P/S of 0.31 and P/B of 0.36.

The outlook remains speculative given persistent losses, but improving cash flow trends and analyst optimism provide catalysts. Key risks include ongoing negative profitability and competitive pressures in genomics. With 57% analyst buy ratings and bullish technical momentum, the stock offers high-risk growth potential for investors comfortable with biotech volatility.

Byrna Technologies Inc

BYRN trades at $4.34, down 10.52% in 24 hours, with a mixed technical outlook showing bullish moving averages but neutral oscillators. The company reported a net loss in 2026 with a negative net income margin of -3.39%, though it maintains a strong gross profit margin of 52.51%. Recent leadership appointments aim to bolster marketing and retail expansion, while Q2 2026 earnings missed estimates with a loss of $0.44 per share.

The outlook is challenged by recent earnings misses and declining revenue, but analyst consensus remains bullish with 71% buy ratings. Key risks include execution in sales turnaround and competitive pressures. Upside depends on successful implementation of new growth initiatives and improved financial performance in upcoming quarters.

Returns comparison

Trailing returns across standard periods

About BioNano Genomics Inc

Bionano Genomics Inc is a life sciences instrumentation company in the genome analysis space. It is engaged in the development and marketing of the Saphyr system, a platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets and to streamline the study of changes in chromosomes.

Read more on BNGO

About Byrna Technologies Inc

Byrna Technologies specializes in less-lethal personal security devices. It develops and manufactures innovative handheld launchers and projectiles designed for self-defense, law enforcement, and private security use.

Read more on BYRN